script.reportAU
Oncology

Nivolumab

Brand: Opdivo

PBAC's latest decision on Nivolumab: Recommended with restriction (2024). Considered for Perioperative treatment (neoadjuvant plus adjuvant) of patients with resectable non-small cell lung cancer (tumours ≥4 cm or node positive) without known EGFR mutations or ALK rearrangements.

PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
36
first 2015
PBS spend
$875M
121,146 scripts · 2024

Eligible population

Adults with resectable non-small cell lung cancer (tumours ≥4 cm or node positive), no known EGFR mutations or ALK rearrangements, WHO performance status 0 or 1.

Therapy area
Oncology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
EFS
Key trials
CM77T, CM816
Comparator
Neoadjuvant nivolumab plus platinum-doublet chemotherapy (main comparator per PSCR)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis versus neoadjuvant nivolumab plus chemotherapy; no numeric ICER presented in public text.
ICER (historical)
$25k/QALY–$35k/QALY across 7 submissions (2016–2024) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.

PBS expenditure

The Australian government paid $875M in PBS benefits for Nivolumab in 2024 across 121,146 scripts, at $7,224 per script.

Submission history

Similar precedents

Open on full dashboard →